Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Albireo Pharma Inc (NQ: ALBO )

35.77 USD -1.47 (-3.95%)
Official Closing Price Updated: 4:00 PM EST, Mar 2, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Albireo Pharma Inc

< Previous 1 2 3 4 5 Next >
Albireo to Present at Cantor Fitzgerald Global Healthcare Conference
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Dr. Patrick Horn, Chief Medical Officer, is... 
From GlobeNewswire News Releases
Albireo to Present at the H.C. Wainwright Global Investment Conference
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo to Present at Wedbush PacGrow Healthcare Conference
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo Reports Second Quarter 2018 Financial Results
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the... 
From GlobeNewswire News Releases
Albireo to Report Second Quarter 2018 Financial Results, and Host Conference Call and Webcast on August 7, 2018
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its second quarter financial results will be... 
From GlobeNewswire News Releases
Factors of Influence in 2018, Key Indicators and Opportunity within Finisar, Albireo Pharma, Corporate Office Properties Trust, Ocean Power Technologies, Depomed, and Potbelly — New Research Emphasize
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Finisar Corporation... 
From GlobeNewswire News Releases
Albireo Appoints Patrick Horn MD, PhD as Chief Medical Officer
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Dr. Patrick Horn as Chief Medical... 
From GlobeNewswire News Releases
Albireo Added to Russell 2000® Index
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it has been added to the Russell 2000® Index as... 
From GlobeNewswire News Releases
Albireo Appoints Jason G. Duncan as General Counsel and Secretary
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Jason G. Duncan as General Counsel... 
From GlobeNewswire News Releases
FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has... 
From GlobeNewswire News Releases
Albireo Elects Anne Klibanski and Stephanie Okey to Board of Directors
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the election of Anne Klibanski, M.D., and Stephanie... 
From GlobeNewswire News Releases
Albireo to Present at Jefferies 2018 Global Healthcare Conference
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo Provides First Quarter 2018 Business Update
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today provided corporate highlights for the beginning of 2018. 
From GlobeNewswire News Releases
Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the first patient has been enrolled in PEDFIC-1, a... 
From GlobeNewswire News Releases
Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live... 
From GlobeNewswire News Releases
Albireo to Present at Deutsche Bank 43rd Annual Health Care Conference
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that findings from two studies that deepen the... 
From GlobeNewswire News Releases
Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The International Liver Congress™ 2018
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that data on a pharmacodynamic marker measured in its... 
From GlobeNewswire News Releases
Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant to five employees of inducement stock... 
From GlobeNewswire News Releases
Albireo to Present at H.C. Wainwright Global Life Sciences Conference
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo to Present Clinical Data on A4250 at The International Liver Congress™ 2018
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that new data from its completed Phase 2 trial of lead... 
From GlobeNewswire News Releases
Albireo to Present at 17th Annual Needham & Company Healthcare Conference
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo Reports Fourth Quarter and Year-End 2017 Financial Results
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the... 
From GlobeNewswire News Releases
Albireo to Report Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call and Webcast on March 15, 2018
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its fourth quarter and year-end 2017 financial... 
From GlobeNewswire News Releases
Albireo to Present at 38th Annual Cowen and Company Health Care Conference
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced... 
From GlobeNewswire News Releases
Albireo Prices $65.0 Million Public Offering of Common Stock
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten... 
From GlobeNewswire News Releases
Albireo Announces Proposed Public Offering of Common Stock
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an underwritten public offering... 
From GlobeNewswire News Releases
Albireo to Receive More than $55 Million(1) in Nondilutive Cash Payments
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Japan’s Ministry of Health, Labor and Welfare... 
From GlobeNewswire News Releases
Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan
Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that subsidiary Elobix AB has entered into an... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback